This site is intended for Healthcare Professionals only.

‘Clinical trials for BioNTech’s cancer vaccines should start this year in Britain’


Share post:

Clinical trials for BioNTech’s cancer vaccines should start this year in Britain, marking an important step towards their possible sale on the open market, the German company’s top executive Ugur Sahin told magazine Der Spiegel.

BioNTech, known for its COVID vaccine with U.S. partner Pfizer, is currently deciding which types of cancer it wants to test its personalized cancer immunotherapies on and the locations where it will conduct the trials, Sahin said.

The company wants these therapies, which are based on messenger RNA (mRNA) technology similar to the one that underpins its COVID-19 vaccine, to soon become a regular treatment for cancer patients.

“We believe that this should be possible for large amounts of patients before 2030,” Sahin said.

The technology for this type of therapy has come a long way, he said.

“In 2014 we needed 3-6 months to create an individualized cancer vaccine, now we need 4-6 weeks. Our aim is to get it significantly under 4 weeks.”


Please enter your comment!
Please enter your name here

Current Issue March 2024

Related articles

RPS joins efforts to boost children’s health in Wales

A group of 20 royal colleges and professional bodies unite to elevate the profile of child health in...

SSPs reactivated for clarithromycin amid surging whooping cough cases

The UK Health Security Agency (UKHSA) has confirmed 2,793 cases of whooping in the first quarter of 2024,...

Insect bites and stings surge: Searches for NHS advice triple

Visit your local pharmacy for advice and treatment of common health conditions, including infected insect bites Insect bites...

RPS Fellowship May 2024 list announced: Benjamin Hannan shines as the youngest Scottish fellow

Hannan joins 783 diverse RPS Fellowship members alongside other new 19 members announced  Benjamin Hannan, director of reform and...